\n\n\n\n\t\t\n\t\t\tCerus\n\t\t\thttp://www.cerus.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tCerus is developing novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs, particularly within the fields of cancer, infectious...More»
\n\t\t\tCerus is developing novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs, particularly within the fields of cancer, infectious disease and blood safety. We are employing our proprietary vaccine platform, often with public domain and proprietary antigens, to develop new therapies for cancer and infectious disease. We have three therapeutic cancer vaccine products in development using our Listeria vaccine platform; one in collaboration with MedImmune, Inc., and two with The Johns Hopkins University. We are also collaborating with BioOne Corporation on the INTERCEPT Blood System, which is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, other pathogens and white blood cells. The INTERCEPT Blood System is based on our Helinx technology for controlling biological replication. We are currently marketing The INTERCEPT Blood System for platelets in Europe.«Less
\n\n\t\t\tOverview
\n\t\t\t\tLocation: \tConcord, CA, United States\n
\n\t\t\t\tTags:\n\t\t\t\tEurope,\n\t\t\t\tPhase I,\n\t\t\t\tplatelets,\n\t\t\t\tCE Mark,\n\t\t\t\tINTERCEPT,\n\t\t\t\tBlood System,\n\t\t\t\tplasma,\n\t\t\t\tmedical\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series A - $50M (10/02/2002)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tCoral Partners,\n\t\t\t\t\t\n\t\tBaxter\n\t\t\t\t
\n\t\t\t